Investigation announced for Investors in NASDAQ: FIXX shares over possible Wrongdoing at Homology Medicines, Inc.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Homology Medicines, Inc.

Investors who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Homology Medicines directors breached their fiduciary duties and caused damage to the company and its shareholders.

Bedford, MA based Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.

On July 21, 2020, a report was published questioning statements by Homology Medicines, Inc. and its officers about the efficacy of HMI-102, the Company’s lead product candidate for treatment of phenylketonuria. The report focused on Homology’s HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102’s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, the report cited an email from Homology’s Chief Communications Officer appearing to indicate the Company’s awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.

Shares of Homology Medicines, Inc. (NASDAQ: FIXX) declined from $30.34 per share in March 2019 to as low as $9.19 per share on September 4, 2020.

Those who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.